A Study of WR 6026 in the Treatment of Pneumocystis Carinii Pneumonia (PCP) in HIV-Infected Patients
Status:
Completed
Trial end date:
1998-07-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy of WR 6026 once daily in the treatment of mild PCP. To evaluate the
safety and tolerance of WR 6026. To assess the correlation between plasma WR 6026
concentrations and outcome/toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)